Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Santoni

Showing results (161-170 of 459) with videos related to

Pageof 46
Sort By:
Molecular Diagnosis & Therapy|March 5, 2016
Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer TherapyFrancesco Piva, Matteo Giulietti, Matteo Santoni, et al.
BMC Cancer|November 20, 2020
Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER<sup>+</sup>HER2<sup>-</sup>Rb wild-type and knock-down in breast cancer cell linesOliviero Marinelli, Emanuela Romagnoli, Federica Maggi, et al.
Therapeutic Advances in Urology|January 24, 2019
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureterMaristella Bianconi, Alessia Cimadamore, Luca Faloppi, et al.
Expert Opinion on Investigational Drugs|February 18, 2021
An update on investigational therapies that target STAT3 for the treatment of cancerMatteo Santoni, Francesca Miccini, Alessia Cimadamore, et al.
Clinical Genitourinary Cancer|August 6, 2019
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety OutcomesVincenzo Di Nunno, Veronica Mollica, Matteo Santoni, et al.
European Urology Focus|March 14, 2021
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical TrialsAlessandro Rizzo, Veronica Mollica, Matteo Santoni, et al.
Future Oncology (London, England)|June 5, 2019
BAP1 in solid tumorsVincenzo Di Nunno, Giorgio Frega, Matteo Santoni, et al.
Critical Reviews in Oncology/Hematology|October 9, 2018
Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumorsFrancesco Carrozza, Matteo Santoni, Francesco Piva, et al.
Chemico-Biological Interactions|December 3, 2014
Resiniferatoxin induces death of bladder cancer cells associated with mitochondrial dysfunction and reduces tumor growth in a xenograft mouse modelValerio Farfariello, Sonia Liberati, Maria Beatrice Morelli, et al.
Oncotarget|November 10, 2016
Post-transcriptional regulation of 5'-untranslated regions of human Transient Receptor Potential Vanilloid type-1 (TRPV-1) channels: role in the survival of glioma patientsMassimo Nabissi, Maria Beatrice Morelli, Antonietta Arcella, et al.
Pageof 46

Showing results (161-170 of 459) with videos related to

Sort By:
Pageof 46
Molecular Diagnosis & Therapy|March 5, 2016
Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer TherapyFrancesco Piva, Matteo Giulietti, Matteo Santoni, et al.
BMC Cancer|November 20, 2020
Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER<sup>+</sup>HER2<sup>-</sup>Rb wild-type and knock-down in breast cancer cell linesOliviero Marinelli, Emanuela Romagnoli, Federica Maggi, et al.
Therapeutic Advances in Urology|January 24, 2019
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureterMaristella Bianconi, Alessia Cimadamore, Luca Faloppi, et al.
Expert Opinion on Investigational Drugs|February 18, 2021
An update on investigational therapies that target STAT3 for the treatment of cancerMatteo Santoni, Francesca Miccini, Alessia Cimadamore, et al.
Clinical Genitourinary Cancer|August 6, 2019
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety OutcomesVincenzo Di Nunno, Veronica Mollica, Matteo Santoni, et al.
European Urology Focus|March 14, 2021
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical TrialsAlessandro Rizzo, Veronica Mollica, Matteo Santoni, et al.
Future Oncology (London, England)|June 5, 2019
BAP1 in solid tumorsVincenzo Di Nunno, Giorgio Frega, Matteo Santoni, et al.
Critical Reviews in Oncology/Hematology|October 9, 2018
Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumorsFrancesco Carrozza, Matteo Santoni, Francesco Piva, et al.
Chemico-Biological Interactions|December 3, 2014
Resiniferatoxin induces death of bladder cancer cells associated with mitochondrial dysfunction and reduces tumor growth in a xenograft mouse modelValerio Farfariello, Sonia Liberati, Maria Beatrice Morelli, et al.
Oncotarget|November 10, 2016
Post-transcriptional regulation of 5'-untranslated regions of human Transient Receptor Potential Vanilloid type-1 (TRPV-1) channels: role in the survival of glioma patientsMassimo Nabissi, Maria Beatrice Morelli, Antonietta Arcella, et al.
Pageof 46